KarMMa-2 Results to be Presented at ASH 2022; No Updates for bbT369 and SC-DARIC33; PBCAR269A Discontinued; 2seventy bio and Precision BioSciences Q3 2022 Earnings Summaries
On Monday, November 7, 2seventy bio released their Q3 2022 earnings results (press release) highlighting Abecma’s (BMS / 2seventy’s BCMA CAR-T) increased revenue. Moreover, preliminary clinical results from Cohorts 2A and 2C of the Ph2 KarMMa-2 in ≥2L HR MM will be presented at ASH 2022 (Dec 10-13). On Tuesday, November 8, Precision BioSciences reported their Q3 2022 financials and business updates (press release) highlighting the discontinuation of PBCAR269A (allogeneic BCMA CAR-T). Below, Celltelligence provides insights on Abecma’s improved efficacy in the KarMMa-2 study, while discussing Precision’s decision to deprioritize its BCMA franchise.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.